<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576705</url>
  </required_header>
  <id_info>
    <org_study_id>IJL-AFHT-TH10</org_study_id>
    <nct_id>NCT01576705</nct_id>
  </id_info>
  <brief_title>Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children</brief_title>
  <acronym>ACTHYF</acronym>
  <official_title>Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Jerome Lejeune</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital Cochin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Jerome Lejeune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the following in very young children with Down syndrome:

        -  the efficacy of systematic treatment with L-thyroxine at controlled doses (clinically
           and by ultrasensitive thyreostimulating hormone (TSH) assay),

        -  the efficacy of systematic folinic acid treatment at a dose of 1 mg/kg/o.i.d,

        -  any interaction between these two treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2012</start_date>
  <completion_date type="Actual">December 14, 2017</completion_date>
  <primary_completion_date type="Actual">December 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMDS (Griffiths Mental Development Scale)</measure>
    <time_frame>12 months</time_frame>
    <description>GMDS for testing and estimate babies psychomotor development from birth to 2 years trough six subscales : Locomotor, Personal-social, Hearing and language, Eye-Hand coordination, Performance.Sub- and General Quotients (GDQ) standard score are based on a mean of 100 and a standard deviation of 16. For children with delayed development, which is the case for children with Down Syndrome, Quotient tables could be not used because sub- and General quotient floors at 50. For each subscale, a raw score was derived from the contributing items. Total raw score was obtained by adding subscale raw scores. Sum of all subscale raw scores was converted into a development age using correspondence table. Subscale and global development quotients were computed by dividing the development age by the chronological age multiplied by 100. For preterm infants, chronological age was corrected taking into account the gestational term. Higher QD's scores show a better psychomotor development outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BL (Brunet Lezine Revised Scale)</measure>
    <time_frame>12 months</time_frame>
    <description>BL includes 4 subscales : Locomotor, Coordination, Language, Sociability. Subscale and global developpemental quotients were computed by dividing the developpemental age by the chronological age multiplied by 100. This kind of formula do not give a min-max outcome. Higher QD's scores show a better psychomotor developpement outcome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Down Syndrome</condition>
  <arm_group>
    <arm_group_label>Thyroxin + folinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroxin+folinic acid placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroxin placebo+ folinic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroxin placebo+ folinic acid placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thyroid hormone and folinic acid</intervention_name>
    <description>thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
    <arm_group_label>Thyroxin + folinic acid</arm_group_label>
    <arm_group_label>Thyroxin placebo+ folinic acid</arm_group_label>
    <arm_group_label>Thyroxin placebo+ folinic acid placebo</arm_group_label>
    <arm_group_label>Thyroxin+folinic acid placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with a karyotype demonstrating homogeneous, free or Robertsonian translocation
             trisomy 21

          -  patient having undergone a cardiac ultrasound not demonstrating any severe heart
             disease

          -  patient aged 6 to 18 months at inclusion

        Exclusion Criteria:

          -  congenital hypothyroidism

          -  hypothyroidism demonstrated by laboratory tests (TSH &gt; 7mUI/l)

          -  presenting or having presented hyperthyroidism

          -  presenting or having presented leukaemia

          -  presenting or having presented West syndrome or any other form of epilepsy or unstable
             neurological disease

          -  presenting or having presented signs of central nervous system distress: stroke,
             postoperative hypoxia, meningitis)

          -  presenting severe heart disease on cardiac ultrasound, with haemodynamic effects

          -  presenting non-controlled cardiac arrhythmia

          -  Apgar &lt; 7 to 5 min at birth

          -  Gestational age &lt; 231 days (33 gestation weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clotilde MIRCHER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jerome Lejeune, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck STURTZ, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Biochemistry and Molecular Genetics, Limoges University, Limoges, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jerome Lejeune</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutlejeune.org/</url>
    <description>Institut Jerome Lejeune</description>
  </link>
  <reference>
    <citation>Blehaut H, Mircher C, Ravel A, Conte M, de Portzamparc V, Poret G, de Kermadec FH, Rethore MO, Sturtz FG. Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status. PLoS One. 2010 Jan 11;5(1):e8394. doi: 10.1371/journal.pone.0008394.</citation>
    <PMID>20084109</PMID>
  </reference>
  <reference>
    <citation>van Trotsenburg AS, Kempers MJ, Endert E, Tijssen JG, de Vijlder JJ, Vulsma T. Trisomy 21 causes persistent congenital hypothyroidism presumably of thyroidal origin. Thyroid. 2006 Jul;16(7):671-80.</citation>
    <PMID>16889491</PMID>
  </reference>
  <reference>
    <citation>van Trotsenburg AS, Vulsma T, van Rozenburg-Marres SL, van Baar AL, Ridder JC, Heymans HS, Tijssen JG, de Vijlder JJ. The effect of thyroxine treatment started in the neonatal period on development and growth of two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab. 2005 Jun;90(6):3304-11. Epub 2005 Mar 8.</citation>
    <PMID>15755847</PMID>
  </reference>
  <reference>
    <citation>Ellis JM, Tan HK, Gilbert RE, Muller DP, Henley W, Moy R, Pumphrey R, Ani C, Davies S, Edwards V, Green H, Salt A, Logan S. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ. 2008 Mar 15;336(7644):594-7. doi: 10.1136/bmj.39465.544028.AE. Epub 2008 Feb 21.</citation>
    <PMID>18296460</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>October 9, 2019</results_first_submitted>
  <results_first_submitted_qc>April 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2020</results_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Down syndrome</keyword>
  <keyword>Young children</keyword>
  <keyword>Psychomotor development</keyword>
  <keyword>Thyroid hormone</keyword>
  <keyword>Folinic acid</keyword>
  <keyword>Psychometric tests</keyword>
  <keyword>GMDS</keyword>
  <keyword>Griffiths</keyword>
  <keyword>Genetic factors</keyword>
  <keyword>Biochemical factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT01576705/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period : 2012-2016 First inclusion : 02/04/2012 Last inclusion : 14/12/2016
Location : Institut Jérôme Lejeune</recruitment_details>
      <pre_assignment_details>As recruitment was nationwide and patients were included at a single centre, screening and randomisation were performed on the same day to minimise visits to the centre. Eligibility of randomised patients for TSH levels per exclusion criterion #8 was thus confirmed retrospectively, and patients with high TSH levels were discontinued.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Thyroxin + Folinic Acid</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg in tablets folinic acid 5 mg in capsules</description>
        </group>
        <group group_id="P2">
          <title>Thyroxin+Folinic Acid Placebo</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg in tablets folinic acid placebo in capsules</description>
        </group>
        <group group_id="P3">
          <title>Thyroxin Placebo+ Folinic Acid</title>
          <description>thyroid hormone and folinic acid: thyroid hormone placebo in tablets folinic acid 5 mg in capsules</description>
        </group>
        <group group_id="P4">
          <title>Thyroxin Placebo+ Folinic Acid Placebo</title>
          <description>thyroid hormone and folinic acid: thyroid hormone placebo in tablets folinic acid placebo in capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>TSH &gt; 7 mIU/L at baseline</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>invalid ICF</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The modified intention-to-treat (mITT) population included all randomized patients who did not prematurely discontinue due to elevated baseline thyroid stimulating hormone (TSH)</population>
      <group_list>
        <group group_id="B1">
          <title>Thyroxin + Folinic Acid</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
        <group group_id="B2">
          <title>Thyroxin+Folinic Acid Placebo</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
        <group group_id="B3">
          <title>Thyroxin Placebo+ Folinic Acid</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
        <group group_id="B4">
          <title>Thyroxin Placebo+ Folinic Acid Placebo</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age at inclusion in months</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.3" spread="3.4"/>
                    <measurement group_id="B2" value="12.2" spread="3.8"/>
                    <measurement group_id="B3" value="12.3" spread="4"/>
                    <measurement group_id="B4" value="12.7" spread="3.3"/>
                    <measurement group_id="B5" value="12.37" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Male or Female</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's height at baseline</title>
          <description>Height measured in cm</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.86" spread="3.88"/>
                    <measurement group_id="B2" value="71.14" spread="5.03"/>
                    <measurement group_id="B3" value="71.13" spread="4.15"/>
                    <measurement group_id="B4" value="71.68" spread="4.36"/>
                    <measurement group_id="B5" value="71.21" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karyotype %</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Free trisomy 21</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Robertsonian translocation</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pregnancy term</title>
          <units>weeks of amenorrhea</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.03" spread="1.37"/>
                    <measurement group_id="B2" value="38.14" spread="0.98"/>
                    <measurement group_id="B3" value="38.29" spread="1.33"/>
                    <measurement group_id="B4" value="37.85" spread="0.99"/>
                    <measurement group_id="B5" value="38.07" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac abnormalities</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Isolated hear murmur</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrioventricular septal defect (AVSD)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TSH</title>
          <units>mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="1.7"/>
                    <measurement group_id="B2" value="4.32" spread="1.52"/>
                    <measurement group_id="B3" value="4.79" spread="1.23"/>
                    <measurement group_id="B4" value="4.45" spread="1.49"/>
                    <measurement group_id="B5" value="4.46" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's weight at baseline</title>
          <description>Weight measured in kg</description>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.30" spread="1.2"/>
                    <measurement group_id="B2" value="8.19" spread="1.42"/>
                    <measurement group_id="B3" value="8.54" spread="1.13"/>
                    <measurement group_id="B4" value="8.62" spread="1.6"/>
                    <measurement group_id="B5" value="8.42" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's head circumference at baseline</title>
          <description>Head circumference measured in cm</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="37"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="41"/>
                    <count group_id="B5" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="1.59"/>
                    <measurement group_id="B2" value="43.55" spread="1.64"/>
                    <measurement group_id="B3" value="43.63" spread="1.55"/>
                    <measurement group_id="B4" value="43.82" spread="1.68"/>
                    <measurement group_id="B5" value="43.63" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GMDS (Griffiths Mental Development Scale)</title>
        <description>GMDS for testing and estimate babies psychomotor development from birth to 2 years trough six subscales : Locomotor, Personal-social, Hearing and language, Eye-Hand coordination, Performance.Sub- and General Quotients (GDQ) standard score are based on a mean of 100 and a standard deviation of 16. For children with delayed development, which is the case for children with Down Syndrome, Quotient tables could be not used because sub- and General quotient floors at 50. For each subscale, a raw score was derived from the contributing items. Total raw score was obtained by adding subscale raw scores. Sum of all subscale raw scores was converted into a development age using correspondence table. Subscale and global development quotients were computed by dividing the development age by the chronological age multiplied by 100. For preterm infants, chronological age was corrected taking into account the gestational term. Higher QD's scores show a better psychomotor development outcome</description>
        <time_frame>12 months</time_frame>
        <population>The main analysis of the primary efficacy endpoint is the adjusted change from baseline in GDQ derived from the Griffith Mental Development Scales (GMDS) at 12 months analysed by ANCOVA adjusted for covariates. Expected Outcome : six points difference in GDQ between any of the three treatment group compared to placebo at 12 months from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Thyroxin + Folinic Acid</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
          <group group_id="O2">
            <title>Thyroxin+Folinic Acid Placebo</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
          <group group_id="O3">
            <title>Thyroxin Placebo+ Folinic Acid</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
          <group group_id="O4">
            <title>Thyroxin Placebo+ Folinic Acid Placebo</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
        </group_list>
        <measure>
          <title>GMDS (Griffiths Mental Development Scale)</title>
          <description>GMDS for testing and estimate babies psychomotor development from birth to 2 years trough six subscales : Locomotor, Personal-social, Hearing and language, Eye-Hand coordination, Performance.Sub- and General Quotients (GDQ) standard score are based on a mean of 100 and a standard deviation of 16. For children with delayed development, which is the case for children with Down Syndrome, Quotient tables could be not used because sub- and General quotient floors at 50. For each subscale, a raw score was derived from the contributing items. Total raw score was obtained by adding subscale raw scores. Sum of all subscale raw scores was converted into a development age using correspondence table. Subscale and global development quotients were computed by dividing the development age by the chronological age multiplied by 100. For preterm infants, chronological age was corrected taking into account the gestational term. Higher QD's scores show a better psychomotor development outcome</description>
          <population>The main analysis of the primary efficacy endpoint is the adjusted change from baseline in GDQ derived from the Griffith Mental Development Scales (GMDS) at 12 months analysed by ANCOVA adjusted for covariates. Expected Outcome : six points difference in GDQ between any of the three treatment group compared to placebo at 12 months from baseline.</population>
          <units>developpement quotient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.96" spread="7.88"/>
                    <measurement group_id="O2" value="51.27" spread="6.48"/>
                    <measurement group_id="O3" value="51.66" spread="6.37"/>
                    <measurement group_id="O4" value="51.67" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BL (Brunet Lezine Revised Scale)</title>
        <description>BL includes 4 subscales : Locomotor, Coordination, Language, Sociability. Subscale and global developpemental quotients were computed by dividing the developpemental age by the chronological age multiplied by 100. This kind of formula do not give a min-max outcome. Higher QD's scores show a better psychomotor developpement outcome.</description>
        <time_frame>12 months</time_frame>
        <population>The main analysis of the secondary efficacy endpoint of the adjusted change from baseline in the BL-R GDQ at 12 months, analysed by ANCOVA adjusted for covariates, is presented in the mITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Thyroxin + Folinic Acid</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
          <group group_id="O2">
            <title>Thyroxin+Folinic Acid Placebo</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
          <group group_id="O3">
            <title>Thyroxin Placebo+ Folinic Acid</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
          <group group_id="O4">
            <title>Thyroxin Placebo+ Folinic Acid Placebo</title>
            <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
          </group>
        </group_list>
        <measure>
          <title>BL (Brunet Lezine Revised Scale)</title>
          <description>BL includes 4 subscales : Locomotor, Coordination, Language, Sociability. Subscale and global developpemental quotients were computed by dividing the developpemental age by the chronological age multiplied by 100. This kind of formula do not give a min-max outcome. Higher QD's scores show a better psychomotor developpement outcome.</description>
          <population>The main analysis of the secondary efficacy endpoint of the adjusted change from baseline in the BL-R GDQ at 12 months, analysed by ANCOVA adjusted for covariates, is presented in the mITT population.</population>
          <units>developpement quotient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.18" spread="6.98"/>
                    <measurement group_id="O2" value="50.64" spread="7.25"/>
                    <measurement group_id="O3" value="51.24" spread="6.46"/>
                    <measurement group_id="O4" value="51.36" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>safety analysis were performed on all randomised patients receiving at least one dose of study treatment Safety population correspond to 174 subjects</desc>
      <group_list>
        <group group_id="E1">
          <title>Thyroxin+Folinic Acid Placebo</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
        <group group_id="E2">
          <title>Thyroxin + Folinic Acid</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
        <group group_id="E3">
          <title>Thyroxin Placebo+ Folinic Acid</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
        <group group_id="E4">
          <title>Thyroxin Placebo+ Folinic Acid Placebo</title>
          <description>thyroid hormone and folinic acid: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm begign, maligant and unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutnaeous tissue disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms begnin, malignant and unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The initial protocol planned for 256 patients, however due to difficulties in recruiting patients, the sample size was subsequently reduced to 175 patients, to obtain 140 evaluable patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Clotilde Mircher</name_or_title>
      <organization>Institut Jérôme Lejeune</organization>
      <phone>00 33 1 56 58 63 00</phone>
      <email>clotilde.mircher@institutlejeune.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

